Table 1.

Patient, tumor, and treatment characteristics for the entire cohort, grade III subgroup, and grade IV subgroup.

Factors	Whole cohort (n = 51)	Grade III (n = 23)	Grade IV (n = 28)	Fisher exact t-test
Median age	13 (4−20)	13 (4− 18)	13 (5− 20)	NA
Median follow-up	19 (2−269)	31 (5− 269)	15.5 (2− 142)	NA
Gender
Male	55% (n = 28)	48% (n = 11)	61% (n = 17)	p = 0.41
Female	45% (n = 23)	52% (n = 12)	39% (n = 11)	p = 0.41
Duration of symptom presentation
≥6 weeks	35% (n = 18)	52% (n = 12)	21% (n = 6)	p = 0.73
<6 weeks	31% (n = 16)	39% (n = 9)	30% (n = 7)	p = 0.73
Symptoms at presentation
Headache	61% (n = 31)	61% (n = 14)	61% (n = 17)	p = 1.0
Seizure	31% (n = 16)	35% (n = 8)	29% (n = 8)	p = 0.76
Cranial nerve deficit	14% (n = 7)	13% (n = 3)	14% (n = 4)	p = 1.0
Location
Cerebrum	69% (n = 35)	78% (n = 18)	61% (n = 17)	p = 0.23
Thalamus	16% (n = 8)	9% (n = 2)	21% (n = 6)	p = 0.27
Midbrain	4% (n = 2)	4% (n = 1)	3.5% (n = 1)	p = 1.0
Cerebellum	6% (n = 3)	0% (n = 0)	11% (n = 3)	p = 0.60
Other	6% (n = 3)	9% (n = 2)	3.5% (n = 1)	p = 0.58
Size
Median (cm)	5 (2.5−10)	5 (2.5− 7)	5 (3− 10)	NA
Extent of resection
Biopsy only	18% (n = 9)	13% (n = 3)	21% (n = 6)	p = 0.49
STR	59% (n = 30)	65% (n = 15)	54% (n = 15)	p = 0.57
GTR	23% (n = 12)	22% (n = 5)	25% (n = 7)	p = 1.0
Radiation and chemotherapy treatment
Median dose of RT	59.4 Gy	59.4 Gy	59.4 Gy	NA
Concurrent CRT	51% (n = 26)	17% (n = 4)	79% (n = 22)	p < 0.0001
CT after RT/CRT	57% (n = 35)	61% (n = 14)	54% (n = 15)	p = 0.77
Concurrent and adjuvant CT	35% (n = 18)	13% (n = 3)	54% (n = 15)	p = 0.003
Temozolomide use	39% (n = 20)	4% (n = 1)	68% (n = 19)	p < 0.0001

NA, not applicable; GTR, gross total resection; STR, sub-total resection; RT, radiation therapy; CT, chemotherapy; CRT, chemoradiation.

Bold indicates significant value (p ≤ 0.05).